Advances in CAR NK Cell Therapy for Targeting and Eradicating Circulating Tumor Cells: Challenges and Solutions for Aging Patients Mini Review DOI Creative Commons
Dmitri Toren, Eugen Ursu, Bogdan Ghilic-Micu

et al.

Ageing & Longevity, Journal Year: 2024, Volume and Issue: 4 2024, P. 157 - 173

Published: Nov. 11, 2024

Chimeric Antigen Receptor (CAR) Natural Killer (NK) cells represent a promising advancement in cancer immunotherapy, particularly for targeting circulating tumor (CTCs) and preventing metastasis. This review examines the latest developments CAR NK cell therapy, including diverse sources, genetic engineering techniques, dual mechanisms of action. Targeting CTCs with shows significant potential aggressive cancers like triple-negative breast (TNBC) pancreatic cancer. The impact aging on function, especially regarding cytotoxicity, cytokine secretion, persistence, poses challenges elderly patients, but strategies such as interleukin-15 metabolic interventions offer solutions. also addresses current limitations, poor persistence immunosuppressive microenvironments low solid infiltration, while proposing combination therapies to enhance effectiveness. Although still earlier clinical stages compared T cells, cells’ safety profile MHC-independent recognition make them versatile therapeutic option. Future directions include optimizing improving developing age-adapted patients. _________________________________________________________________________________________ Keywords: Circulating (CTCs), Cell Therapy, Aging

Language: Английский

Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors? DOI Creative Commons

Daisy Bhatia,

Riccardo Dolcetti, Roberta Mazzieri

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: March 15, 2025

Abstract In the last two decades, novel and promising cell-based therapies have populated treatment landscape for haematological tumors. However, commonly exploited T NK show limited applicability to solid This is mainly given by impaired tumor trafficking capability effector activity of these cells within a highly immunosuppressive microenvironment. Myeloid spontaneously home tumors can thus be reprogrammed and/or engineered directly attack or locally selectively deliver therapeutically relevant payloads that may improve efficacy immunotherapy against difficult-to-access context myeloid therapies, adoptive transfer monocytes has often been overshadowed infusion differentiated macrophages hematopoietic stem cell transplantation despite their therapeutic potential. Here, we summarize recent improvements benefits using tumors, current clinical applications challenges use as well some possible strategies overcome them.

Language: Английский

Citations

1
CAR-NK cell therapy: a potential antiviral platform DOI Creative Commons

Ming-Hao Lin,

Lijuan Hu, Jeffrey S. Miller

et al.

Science Bulletin, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma DOI Creative Commons

Sijia Yan,

Xi Ming,

Rubing Zheng

et al.

Cancer Medicine, Journal Year: 2025, Volume and Issue: 14(6)

Published: March 1, 2025

ABSTRACT Background As a rapidly developing therapeutic method, targeted therapy plays an important role in the treatment of multiple myeloma. In recent years, mature B cell antigen‐targeting has brought new hope for patients with refractory/relapsed disease. While increasing number relapse are exposed to this type drug, changing target may be effective strategy relapse/refractory Objectives The expression G protein‐coupled receptor, class C Group 5 member D (GPRC5D), on surface myeloma tumor cells makes it possible therapy, and relevant studies progress. Results & Conclusions review aims systematically summarize current advancements GPRC5D‐targeted therapies myeloma, thereby providing valuable insights foundation future studies.

Language: Английский

Citations

0
The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy DOI
Vibor Milunović, Dora Dragčević,

Martina Bogeljić Patekar

et al.

Current Treatment Options in Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

Language: Английский

Citations

0
CAR-NK Cells for Haematological Cancers DOI
Mohammadamin Noorafrooz, Robert Peter Gale,

Ramin Noorafrooz

et al.

Best Practice & Research Clinical Haematology, Journal Year: 2025, Volume and Issue: unknown, P. 101631 - 101631

Published: May 1, 2025

Language: Английский

Citations

0
Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape DOI Creative Commons

Yizhao Chen,

Qianling Xin,

Mengjuan Zhu

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 28, 2024

Immune cell therapy based on chimeric antigen receptor (CAR) technology platform has been greatly developed. The types of CAR immune have expanded from T cells to innate such as NK and macrophages, the diseases treated hematological malignancies non-tumor fields infectious autoimmune diseases. Among them, CAR-T CAR-NK observed examples rapid remission in approved clinical trials, but efficacy is unstable plagued by tumor resistance. Trogocytosis a special phenomenon intercellular molecular transfer that common system achieved recipient through acquisition internalization donor cell-derived molecules mediates effects. Recently, novel short-term drug resistance mechanism trogocytosis proposed, bidirectional exchange between triggered partially explains long-term relapse after treatment with cells. In this review, we summarize research progress immunotherapy, discuss influencing factors its direct indirect interference emphasize can further release potential therapy.

Language: Английский

Citations

2
Advances in CAR NK Cell Therapy for Targeting and Eradicating Circulating Tumor Cells: Challenges and Solutions for Aging Patients Mini Review DOI Creative Commons
Dmitri Toren, Eugen Ursu, Bogdan Ghilic-Micu

et al.

Ageing & Longevity, Journal Year: 2024, Volume and Issue: 4 2024, P. 157 - 173

Published: Nov. 11, 2024

Chimeric Antigen Receptor (CAR) Natural Killer (NK) cells represent a promising advancement in cancer immunotherapy, particularly for targeting circulating tumor (CTCs) and preventing metastasis. This review examines the latest developments CAR NK cell therapy, including diverse sources, genetic engineering techniques, dual mechanisms of action. Targeting CTCs with shows significant potential aggressive cancers like triple-negative breast (TNBC) pancreatic cancer. The impact aging on function, especially regarding cytotoxicity, cytokine secretion, persistence, poses challenges elderly patients, but strategies such as interleukin-15 metabolic interventions offer solutions. also addresses current limitations, poor persistence immunosuppressive microenvironments low solid infiltration, while proposing combination therapies to enhance effectiveness. Although still earlier clinical stages compared T cells, cells’ safety profile MHC-independent recognition make them versatile therapeutic option. Future directions include optimizing improving developing age-adapted patients. _________________________________________________________________________________________ Keywords: Circulating (CTCs), Cell Therapy, Aging

Language: Английский

Citations

0